Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00135395
Status:
COMPLETED
Last Update Posted:
2010-02-05
First Post:
2005-08-25
Brief Title:
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase IIIb Open -Label Randomized Multi-center Study Comparing the Antiviral Efficacy Safety and Effect on Serum Lipids of AtazanavirRitonavir Versus LopinavirRitonavir in Combination With Two Nucleoside or Nucleotide Reverse Transcriptase Inhibitors NRTIs in HIV-1 Infected Subjects Experiencing Their First Virologic Failure While Receiving a NNRTI-containing HAART Regimen
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the anti-HIV efficacy safety and effect of serum lipids of two boosted protease inhibitor-based HAART regimens ARVRTV v LPVRTV in HIV-1 infected subjects who have experienced their first virologic failure while receiving a NNRTI-containing HAART regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None